Study Name: A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Pa
20 locations found
- 1220.48.0004 Boehringer Ingelheim Investigational Site
Location: Birmingham, Alabama
- 1220.48.0091 Boehringer Ingelheim Investigational Site
Location: North Little Rock, Arkansas
- 1220.48.0018 Boehringer Ingelheim Investigational Site
Location: Oceanside, California
- 1220.48.0078 Boehringer Ingelheim Investigational Site
Location: Fort Lauderdale, Florida
- 1220.48.0095 Boehringer Ingelheim Investigational Site
Location: Palm Harbor, Florida
- 1220.48.0039 Boehringer Ingelheim Investigational Site
Location: Columbus, Georgia
- 1220.48.0013 Boehringer Ingelheim Investigational Site
Location: Chicago, Illinois
- 1220.48.0087 Boehringer Ingelheim Investigational Site
Location: Baton Rouge, Louisiana
- 1220.48.0027 Boehringer Ingelheim Investigational Site
Location: Framingham, Massachusetts
- 1220.48.0065 Boehringer Ingelheim Investigational Site
Location: Springfield, Massachusetts
- 1220.48.0023 Boehringer Ingelheim Investigational Site
Location: Tupelo, Mississippi
- 1220.48.0066 Boehringer Ingelheim Investigational Site
Location: Neptune, New Jersey
- 1220.48.0012 Boehringer Ingelheim Investigational Site
Location: New York, New York
- 1220.48.0021 Boehringer Ingelheim Investigational Site
Location: Winston-Salem, North Carolina
- 1220.48.0058 Boehringer Ingelheim Investigational Site
Location: Portland, Oregon
- 1220.48.0063 Boehringer Ingelheim Investigational Site
Location: Arlington, Texas
- 1220.48.0029 Boehringer Ingelheim Investigational Site
Location: Austin, Texas
- 1220.48.0071 Boehringer Ingelheim Investigational Site
Location: Dallas, Texas
- 1220.48.0017 Boehringer Ingelheim Investigational Site
Location: Dallas, Texas
- 1220.48.0081 Boehringer Ingelheim Investigational Site
Location: Forth Worth, Texas
|